Orion Portfolio Solutions LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 12.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,263 shares of the medical research company's stock after selling 445 shares during the period. Orion Portfolio Solutions LLC's holdings in Edwards Lifesciences were worth $310,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. American National Bank increased its stake in shares of Edwards Lifesciences by 99.1% in the first quarter. American National Bank now owns 233 shares of the medical research company's stock worth $27,000 after buying an additional 116 shares during the last quarter. Core Alternative Capital increased its stake in Edwards Lifesciences by 513.2% during the first quarter. Core Alternative Capital now owns 233 shares of the medical research company's stock valued at $27,000 after purchasing an additional 195 shares during the last quarter. Rinkey Investments bought a new stake in Edwards Lifesciences during the fourth quarter valued at $29,000. JJJ Advisors Inc. increased its stake in Edwards Lifesciences by 79.1% during the first quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company's stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. Finally, Gemmer Asset Management LLC bought a new stake in Edwards Lifesciences during the first quarter valued at $36,000. Institutional investors own 81.33% of the company's stock.
Get Edwards Lifesciences alerts:Analyst Ratings Changes
Several research firms have weighed in on EW. Truist Financial lowered their target price on shares of Edwards Lifesciences from $117.00 to $112.00 and set a "buy" rating for the company in a research note on Thursday, September 22nd. Stifel Nicolaus lowered their target price on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Cowen lowered their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Cowen lowered their price target on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Finally, Morgan Stanley lowered their price target on shares of Edwards Lifesciences from $136.00 to $119.00 and set an "overweight" rating for the company in a research report on Friday, July 15th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $125.81.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the company's stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $95.88, for a total transaction of $1,905,615.00. Following the completion of the sale, the chief executive officer now directly owns 166,853 shares of the company's stock, valued at $15,997,865.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the company's stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $95.88, for a total transaction of $1,905,615.00. Following the completion of the sale, the chief executive officer now directly owns 166,853 shares of the company's stock, valued at $15,997,865.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Bernard J. Zovighian sold 4,811 shares of the company's stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total transaction of $498,708.26. Following the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,128 shares of company stock valued at $8,223,839. 1.29% of the stock is currently owned by corporate insiders.Edwards Lifesciences Price Performance
Shares of NYSE EW opened at $83.59 on Tuesday. Edwards Lifesciences Co. has a twelve month low of $82.92 and a twelve month high of $131.73. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $51.82 billion, a price-to-earnings ratio of 36.19, a PEG ratio of 2.50 and a beta of 1.14. The firm has a 50-day moving average of $96.82 and a two-hundred day moving average of $101.51.
Edwards Lifesciences (NYSE:EW – Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, meeting analysts' consensus estimates of $0.63. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the company earned $0.64 EPS. Edwards Lifesciences's revenue was down .2% on a year-over-year basis. As a group, analysts expect that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.
Edwards Lifesciences Company Profile
(Get Rating)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
See Also
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Is the Market Overreacting with Shopify Stock?
- MO Money: Why Altria Group Stock is Rallying
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.